| Brandi-lee Gonzales, OTR/L | |
|
Brian D. Allgood Army Community Hospital (bdaach), Unit #15245; Bldg 3031, Apo, AP 96271 | |
| (315) 737-7410 | |
| Not Available |
| Full Name | Brandi-lee Gonzales |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | Brian D. Allgood Army Community Hospital (bdaach), Apo, Armed Forces Pacific |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639819782 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT60993488 (Washington) | Secondary |
| 225X00000X | Occupational Therapist | OT-2087 (Hawaii) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Brandi-lee Gonzales, OTR/L Bdaach Unit 15245, Apo, AP 96271-5245 Ph: (315) 737-7410 | Brandi-lee Gonzales, OTR/L Brian D. Allgood Army Community Hospital (bdaach), Unit #15245; Bldg 3031, Apo, AP 96271 Ph: (315) 737-7410 |
News Archive
Cryoport, Inc., the leading provider of advanced cryogenic logistics solutions for the life sciences industry, today announced that its validated cryogenic logistics solution will support future clinical trials for Opexa Therapeutics' lead personalized T-cell immunotherapy programs for Multiple Sclerosis ("MS") and Neuromyelitis Optica ("NMO").
The 217,000 Idahoans, 15% of the state's population, who rely on Medicaid for basic health services, are bracing for bad news from state lawmakers - more cuts to their health care safety net.
Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.
› Verified 9 days ago
Jameail Wilson, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 51 Mdg/ Sgoy, Unit 2060, Apo, AP 96278 Phone: 315-784-2157 | |
Sam Kim, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Brian D. Allgood Army Community Hospital (bdaach), Unit #15245; Bldg 3031, Apo, AP 96271 Phone: 315-737-1184 | |
Mrs. Mallory Maray Woodard, OTR/L, CLT Occupational Therapist Medicare: Medicare Enrolled Practice Location: Unit 2060, Apo, AP 96278 Phone: 500-578-4871 Fax: 505-784-3625 | |
Holly Thompson, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Bdaach, 549th Hospital Center Usag Humphrey's, Bldg #3030, Apo, AP 96271 Phone: 909-735-9036 | |
Julia E Meurling, MSOT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Brian D. Allgood Army Community Hospital (bdaach), Unit 15245; Bldg 3031, Apo, AP 96271 Phone: 956-533-5811 | |
Mrs. Keila Michele Newell, OTR/ L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: Unit 45002 Box 349, Apo, AP 96337 Phone: 080-507-00564 |